Terminology Service for NFDI4Health
All terms in BAO
| Label | Id | Description |
|---|---|---|
| percent activation normalization | BAO_0001104 | |
| tarsal tunnel syndrome | DOID_12526 | |
| knowledge based scoring function | BAO_0002402 | |
| DrugScore scoring function | BAO_0002403 | |
| sarcocystosis | DOID_9640 | [A coccidiosis that involves infection of the intestine and muscles of humans and animals caused by an intracellular protozoan parasite of genus Sarcocystis. The symptoms include mild fever, diarrhea, chills, vomiting, muscle swelling, erythema, muscle tenderness,cough, arthralgia, transient pruritic rashes, headache, malaise and lymphadenopathy.] |
| potentials of mean force scoring function | BAO_0002404 | |
| receptor based pharmacophore search | BAO_0002405 | [The receptor-based ensemble of steric and electronic features that is necessary to ensure the optimal supramolecular interactions with a specific biological target structure and to trigger (or to block) its biological response.] |
| CoMFA pharmacophore search | BAO_0002406 | |
| GRID pharmacophore search | BAO_0002407 | |
| SPROUT pharmacophore search | BAO_0002408 | |
| babesiosis | DOID_9643 | [A parasitic protozoa infectious disease that has_symptommild fevers and has_symptom anemia described as malaria-like symptoms caused by a protozoan of genus Babesia, which reproduce in red blood cells and cause hemolytic anemia. They are transmitted by Ixodid ticks or by blood transfusion. Babesiosis is a zoonotic disease.] |
| secondary structure analysis method | BAO_0002409 | |
| congenital nystagmus | DOID_9649 | [A pathologic nystagmus, present at birth, characterized by involuntary, rhythmic eye movements; oscillations are usually horizontal in direction.] |
| CHARMM polarizable | BAO_0002400 | |
| enzyme-multiplied immunoassay technique | BAO_0002401 | [Enzyme multiplied immunoassay technique, or EMIT, is a common method for screening urine and blood for drugs, both legal or illicit. A mix and read protocol has been developed that is exceptionally simple and rapid. The most widely used applications for EMIT are for therapeutic drug monitoring (serum) and as a primary screen for abused drugs and their metabolites (urine).] |
| EC 5.1.1.1 (alanine racemase) inhibitor | CHEBI_75595 | |
| EC 3.6.5.* (hydrolases acting on GTP; involved in cellular and subcellular movement) inhibitor | CHEBI_132771 | |
| EC 6.3.2.4 (D-alanine--D-alanine ligase) inhibitor | CHEBI_75598 | |
| EC 3.6.5.5 (dynamin GTPase) inhibitor | CHEBI_132772 | |
| EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor | CHEBI_75599 |